• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AstraZeneca PLC – ADR to Join the NASDAQ-100 Index Beginning February 22, 2022

    2/10/22 5:00:00 PM ET
    $AZN
    $NDAQ
    $XLNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance
    Get the next $AZN alert in real time by email

    NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that AstraZeneca PLC – ADR (NASDAQ:AZN), will become a component of the NASDAQ-100 Index® (NASDAQ:NDX) and the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) prior to market open on Tuesday, February 22, 2022. AstraZeneca PLC – ADR will replace Xilinx, Inc. (NASDAQ:XLNX) in the NASDAQ-100 Index® and the NASDAQ-100 Equal Weighted Index.

    For more information about the company, go to https://www.astrazeneca.com.

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

    Media Contact

    Emily Pan

    [email protected]

    +1 (646) 637-3964

    Issuer & Investor Contact

    Index Client Services

    [email protected]

    The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    - NDAQG -



    Primary Logo

    Get the next $AZN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN
    $NDAQ
    $XLNX

    CompanyDatePrice TargetRatingAnalyst
    Nasdaq Inc.
    $NDAQ
    11/20/2025$110.00Equal-Weight → Overweight
    Morgan Stanley
    AstraZeneca PLC
    $AZN
    10/27/2025Buy
    Jefferies
    AstraZeneca PLC
    $AZN
    10/16/2025Hold → Sell
    Deutsche Bank
    Nasdaq Inc.
    $NDAQ
    7/25/2025$115.00Neutral → Buy
    UBS
    Nasdaq Inc.
    $NDAQ
    4/17/2025$91.00Neutral → Buy
    Redburn Atlantic
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    Nasdaq Inc.
    $NDAQ
    4/8/2025$74.00Overweight → Equal-Weight
    Morgan Stanley
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    More analyst ratings

    $AZN
    $NDAQ
    $XLNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

    New capacity at AstraZeneca's Fredrick and Gaithersburg facilities will accelerate production of cancer, rare and chronic disease medicines Fourth major US manufacturing investment announced this year, advancing AstraZeneca's historic $50 billion commitment to medicines manufacturing and R&D AstraZeneca today announces plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials. The investment will

    11/21/25 2:05:00 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SGX Group to introduce Global Listing Board in Landmark Partnership with Nasdaq

    The two leading exchanges will create a new listing framework that bridges the U.S. and Singapore capital markets by enabling companies to raise capital, enhance visibility and access investors with ease SINGAPORE and NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- SGX Group (Singapore Exchange) and Nasdaq, Inc. (NASDAQ:NDAQ) today announced a partnership to simplify dual listings in the United States and Singapore, enabling companies with a market capitalisation of S$2 billion and above to access global capital, investors and liquidity through a harmonised cross-border listing framework that bridges the two markets. Scheduled to go live around mid-2026, this Global Listing Board deepens col

    11/19/25 7:00:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Nasdaq Executives to Present at Upcoming Investor Conferences

    NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) will be presenting at the following conferences with webcasts available at Nasdaq's Investor Relations website: ir.nasdaq.com/events.cfm. Who:Sarah Youngwood, Executive Vice President and CFO, NasdaqWhat:J.P. Morgan 2025 Ultimate Services Investor ConferenceWhen:Wednesday, November 18, 20252:00 PM ET Who:Sarah Youngwood, Executive Vice President and CFO, NasdaqWhat:2025 RBC Capital Markets Global Technology, Internet, Media & Telecommunications ConferenceWhen:Tuesday, November 19, 202510:40AM ET  Who:Sarah Youngwood, Executive Vice President and CFO, NasdaqWhat:UBS Global Technology and AI ConferenceWhen:Tuesday, December 2,

    11/13/25 4:05:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CSO Skule Jeremy sold $179,767 worth of shares (2,105 units at $85.40), decreasing direct ownership by 2% to 84,974 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    11/5/25 4:00:08 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    EVP, CSO Skule Jeremy sold $185,703 worth of shares (2,105 units at $88.22) and covered exercise/tax liability with 1,262 shares, decreasing direct ownership by 4% to 87,079 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    10/3/25 4:00:08 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    EVP, CSO Skule Jeremy sold $196,228 worth of shares (2,105 units at $93.22), decreasing direct ownership by 2% to 90,446 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    9/4/25 4:00:11 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    11/20/25 8:31:49 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    11/17/25 12:52:48 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    11/14/25 10:12:38 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $NDAQ
    $XLNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zollar Alfred W bought $203,970 worth of shares (2,542 units at $80.24), increasing direct ownership by 5% to 49,293 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    11/14/24 4:29:16 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Torgeby Johan bought $705,880 worth of shares (14,000 units at $50.42), increasing direct ownership by 165% to 22,466 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    10/25/23 4:02:10 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NASDAQ upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded NASDAQ from Equal-Weight to Overweight and set a new price target of $110.00

    11/20/25 7:58:08 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Jefferies resumed coverage on AstraZeneca

    Jefferies resumed coverage of AstraZeneca with a rating of Buy

    10/27/25 8:41:53 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca downgraded by Deutsche Bank

    Deutsche Bank downgraded AstraZeneca from Hold to Sell

    10/16/25 8:19:10 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $NDAQ
    $XLNX
    Leadership Updates

    Live Leadership Updates

    View All

    Puro.earth Secures €11 M Series B Financing Led by Nasdaq with Participation from Fortum Innovation & Venturing to strengthen its supplier infrastructure

    HELSINKI, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Puro.earth, a leading carbon-crediting platform for engineered carbon dioxide removal (CDR), today announced it has raised €11 million in a Series B funding round led by Nasdaq with participation from Fortum Innovation & Venturing. Puro.earth will deploy this funding to strengthen the infrastructure that supports its best-in-class certification journey for suppliers. Key initiatives include enabling more frequent issuance of high-integrity carbon removal credits, facilitating offtake agreements, and advancing open integration of digital measurement, reporting, and verification (dMRV) tools. The new investment builds on a period of strong gr

    9/4/25 7:00:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Thomson Reuters Corp to Join the Nasdaq-100 Index® Beginning July 28, 2025

    NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Thomson Reuters Corp (NASDAQ:TRI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX®) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 28, 2025. Thomson Reuters Corp will replace ANSYS, Inc. (NASDAQ:ANSS) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted™ Index. ANSYS, Inc. will also be removed from the Nasdaq-100 Tech Sector™ Index (NASDAQ:NDXT), the Nasdaq-100 Technology Sector Market-Cap Weighted™ Index (NDXTMC™), the Nasdaq-100 Technology Sector Adjusted Market-Cap Weighted™ Index (NDXT10™), the Nasdaq-100 ESG™ Index (NASDAQ:ND

    7/18/25 8:00:00 PM ET
    $ANSS
    $NDAQ
    $TRI
    Computer Software: Prepackaged Software
    Technology
    Investment Bankers/Brokers/Service
    Finance

    Nasdaq Welcomes 142 IPOs in the First Half of 2025

    Highest volume of listings and capital raise in the first half of the year since 2021 Maintained leadership in switches - crossed $3 trillion in market value transferred since 2005 Driving smart policy reforms to improve regulatory processes for public companies NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) announced today that in the first half of 2025, it welcomed 142 listings (IPOs), raising a total of $19.2 billion. A total of 83 operating companies and 59 SPACs listed on Nasdaq during the first six months of 2025, representing an 86% win-rate of Nasdaq-eligible listings in the U.S. market, and extending Nasdaq's leadership to 46 consecutive quarters. In add

    7/1/25 8:05:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Financials

    Live finance-specific insights

    View All

    Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

    Baxdrostat demonstrated a statistically significant placebo-adjusted reduction of 13.9 mmHg in night-time ambulatory systolic blood pressure at 12 weeks with a safety profile consistent with the BaxHTN trial Full results presented at the American Heart Association Scientific Sessions 2025 Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care.1 Efficacy was observed throughout the

    11/9/25 4:33:00 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasdaq Announces Quarterly Dividend of $0.27 Per Share

    NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (NASDAQ:NDAQ) has declared a regular quarterly dividend of $0.27 per share on the company's outstanding common stock. The dividend is payable on December 19, 2025 to shareholders of record at the close of business on December 5, 2025. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. About Nasdaq Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and t

    10/21/25 7:01:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Nasdaq Reports Third Quarter 2025 Results; Surpassing $1 Billion in Solutions Quarterly Revenue and $3 Billion in ARR

    NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (NASDAQ:NDAQ) today reported financial results for the third quarter of 2025. Third quarter 2025 net revenue1 was $1.3 billion, an increase of 15% over the third quarter of 2024, or up 11% on an organic2 basis. This included Solutions3 revenue growing 15%, or up 10% on an organic basis.Annualized Recurring Revenue (ARR)4 of $3.0 billion increased 10% over the third quarter of 2024, or up 9% on an organic basis. Annualized SaaS revenue increased 12%, and represented 38% of ARR.Financial Technology revenue of $457 million increased 23% over the third quarter of 2024, or 13% on an organic basis.Index revenue of $206 million grew 13%, w

    10/21/25 7:00:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/12/24 3:53:01 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G filed by Nasdaq Inc.

    SC 13G - NASDAQ, INC. (0001120193) (Subject)

    11/8/24 10:52:39 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/4/24 1:18:47 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance